Cerenovus, Inc. appears in FDA device records as the applicant behind P990040, the premarket approval covering the TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System. The original approval order describes the device as indicated for embolization of cerebral arteriovenous malformations when presurgical devascularization is desired, and lists it under product code KGG as a tissue adhesive for use in embolization of brain arteriovenous malformations. Later supplements document additional scope, including a procedural set and a post-approval study protocol. The supplied filings show two linked PMA records, both approved, and no recall records. [1][2][4]
The original approval and its stated indication
P990040 was received on July 16, 1999, and approved on September 25, 2000, with a Federal Register notice date of October 20, 2000. The approval statement covers the TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System and states the indication for embolization of cerebral arteriovenous malformations when presurgical devascularization is desired. The filing carries product code KGG, device class 3, and Neurology advisory committee review, with no expedited review flag. [2]
A separate FDA listing record identifies the proprietary name TRUFILL n-Butyle Cyanoacrylate under the classification name tissue adhesive for use in embolization of brain arteriovenous malformations, product code KGG. The same classification and product code appear in the openFDA fields attached to the P990040 records. [10][2]
Supplement S034 and the procedural set
Supplement P990040/S034 was filed on February 3, 2025, amended on September 16, 2025, and noticed as approved on December 16, 2025. The approval letter addresses the TRUFILL n-BCA Liquid Embolic System (LES) and the TRUFILL n-BCA Liquid Embolic System Procedural Set, and lists product code SGU. The letter is addressed to a regulatory affairs contact at the Miami, Florida address used in the filing. [9][4]
The Summary of Safety and Effectiveness Data for S034 gives the device generic name as neurovascular liquid embolic agent and lists device pro codes SGU and KGG. It notes that the original PMA has supplements and that the device description, function or indication may have changed, so the labeling shown is the version at the time of approval. The summary's approval specifications point to device labeling for directions for use, hazards, contraindications, warnings, precautions and adverse events, and to the approval order for post-approval requirements. [4][3]
Labeling components and the post-approval study protocol
The revised 2025 labeling for the TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System lists n-Butyl Cyanoacrylate sterilized using dry heat and ethylene oxide gas, tantalum powder sterilized using irradiation, and ethiodized oil sterilized using moist heat. The document carries a 2009-2025 Johnson & Johnson copyright line and a revision date of 2025/12. Its symbol legend includes MR Conditional, radiopaque, nonpyrogenic, do not reuse, do not resterilize and do not autoclave. [5]
Supplement P990040/S037 was received on February 2, 2026, and approved on October 23, 2026, under the supplement reason postapproval study protocol and the Normal 180 Day Track No User Fee supplement type. The approval statement describes approval of the protocol for the TRUFILL post-approval study, submitted to comply with conditions of approval outlined in the approval order for P990040/S034. The record carries product code KGG and Neurology advisory committee review. [1]
What the filing record does and does not establish
The supplied collection contains two linked PMA records, both with approved decisions, and no recall records; the record sample likewise shows two approved decisions. These counts describe the supplied filings as of the snapshot date and are not measures of total portfolio, sales or safety performance. The PMA database page for P990040 notes that the device has supplements and that the device description, function or indication may have changed, directing readers to the supplements for current information. [3][1][2]
The Johnson & Johnson copyright line appears in the device labeling as published by Cerenovus, Inc.; the public documents do not otherwise establish a corporate ownership structure, headquarters, website or commercial availability. The Miami address is the applicant address used in FDA correspondence and labeling, not a verified headquarters. [5][9]

